Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CK-3773274- Granules in · 1 trial · 2 indications
Subject incidence of AEs, SAEs, and reduced LVEF
| Arm | Type | Description |
|---|---|---|
| CK-3773274 for SAD Cohorts | EXPERIMENTAL | Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of CK-3773274 |
| Placebo for SAD Cohorts | PLACEBO_COMPARATOR | Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of placebo |
| CK-3773274 for MAD Cohorts | EXPERIMENTAL | Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of CK-3773274 |
| Placebo for MAD Cohorts | PLACEBO_COMPARATOR | Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of placebo |
| CK-3773274 for CYP2D6 Cohort | EXPERIMENTAL | Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of CK-3773274 |
| Placebo for CYP2D6 Cohort | PLACEBO_COMPARATOR | Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of placebo |
| Food Effect | EXPERIMENTAL | Subjects will be administered CK-3773274 with and without food in a randomized cross-over fashion |
| Relative Bioavailability | EXPERIMENTAL | Subjects will be administered CK-3773274 as granules in a capsule and as a tablet in a randomized cross-over fashion. |
| Name | Type | Description |
|---|---|---|
| CK-3773274 - Granules in Capsule | DRUG | CK-3773274 formulated as granules in capsule |
| Placebo - Granules in Capsule | DRUG | Placebo formulated as granules in capsule |
| CK-3773274 - Tablets | DRUG | CK-3773274 formulated as tablets |
Inclusion Criteria: 1. Males and females (of non-childbearing potential) between 18 and 55 years of age, inclusive 2. Body weight \> 55.0 kg and body mass index within 18.0 to 32.0 kg/m2, inclusive 3. Normal cardiac structure and function, or if abnormalities are present, they are deemed not clinic...
CK-3773274 is an investigational small molecule being developed for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, a cardiovascular condition. It is currently in Phase 1 clinical development and has not been approved by the FDA.
CK-3773274 is being developed by Cytokinetics, Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol CYTK. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug.
CK-3773274 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not received FDA approval and is still being studied for safety and dosing in humans.
CK-3773274 has one completed Phase 1 trial, NCT03767855, titled "A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects." This randomized, double-blind, placebo-controlled study enrolled 114 participants in the United States, including healthy volunteers.
No alternative names for CK-3773274 have been reported. The drug is identified solely by its code name CK-3773274 in clinical trial registries and by its developer, Cytokinetics, Incorporated.